Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teijin Pharma’s Gout Drug Obtains Marketing Authorization In Europe

This article was originally published in PharmAsia News

Executive Summary

Teijin Pharma announced May 7 that its licensee for the EU, Paris-based Ipsen, was granted marketing authorization by the European Commission for TMX-67 (febuxostat) for the treatment of chronic hyperuricemia in gout. Ipsen submitted the application to the EMEA in August 2006 and received a positive opinion this past February. TMX-67 is a non-purine selective inhibitor of xanthine oxidase with a different structure than allopurinol. Ispen will market the drug under the name of Adenuric. (Click here for more - Japanese language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts